Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia (NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing.
According to a SEC filing dated February 17, 2026, Opaleye Management Inc. sold 180,000 shares of Liquidia during the fourth quarter of 2025. The estimated value of the trade was approximately $5.12 million, based on the average closing price for the quarter. The fund ended the period with 2,435,000 shares, with the quarter-end value of the stake increasing by $25.52 million due to both trade activity and stock appreciation.
Opaleye Management Inc. trimmed its Liquidia position, which now accounts for 11.21% of reportable AUM.
Top holdings after the filing:
NASDAQ:HROW: $191.34 million (25.2% of AUM)
NASDAQ:LQDA: $84.98 million (11.2% of AUM)
NASDAQ:ETON: $48.36 million (6.4% of AUM)
NASDAQ:RYTM: $35.32 million (4.7% of AUM)
NASDAQ:APGE: $29.31 million (3.9% of AUM)
As of February 17, 2026, shares were priced at $33.84, up 105.7% over the past year, outperforming the S&P 500 by 97.0 percentage points.
Metric | Value |
|---|---|
Price (as of market close 2/17/26) | $33.84 |
Market capitalization | $2.94 billion |
Revenue (TTM) | $69.22 million |
Net income (TTM) | ($121.85 million) |
Products include YUTREPIA, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension, and distribution of generic treprostinil injection in the United States.
Revenue is primarily generated through the development, manufacturing, and commercialization of proprietary and generic therapies targeting unmet needs in pulmonary arterial hypertension.
The company targets healthcare providers and patients in the United States requiring advanced therapies for pulmonary arterial hypertension and related conditions.
Liquidia is a biopharmaceutical company focused on innovative therapies for pulmonary arterial hypertension, leveraging proprietary drug delivery technologies. The company’s strategy centers on addressing unmet medical needs through differentiated product formulations and expanding its portfolio in the United States market. Liquidia’s competitive advantage lies in its specialized expertise in inhaled drug delivery and its ability to commercialize both branded and generic therapies within a highly regulated sector.
Opaleye Management, a Massachusetts-based investment manager, recently disclosed a sale of approximately $5.1 million worth of Liquidia stock. Here’s how investors may want to think about it.
